In this CMEO Snack, expert faculty will discuss global HIV treatment guidelines and available ART regimens, including standard and long-acting options, with a focus on selecting optimal, evidence-based ART tailored to individual patient needs and preferences. Faculty will also explore simplification and switching of treatments, pre-switch evaluation, identification of heavily treatment-experienced patients and those requiring special considerations, counseling on dose frequency, and the importance of culturally responsive, patient-centered communication across diverse global settings.
In this CMEO Snack, expert faculty will discuss recent clinical trial and real-world data on the efficacy and safety of novel and emerging HIV therapies, including LAIs, and how treatment guidelines have evolved across global frameworks. Faculty will also examine how emerging evidence may shape the landscape of future clinical practice in different regions.
In this CMEO Snack, faculty will discuss strategies for addressing these ongoing gaps in HIV care, including integration of optimized workflows that entail patient counseling, shared decision-making, interprofessional collaboration, and individualized treatment to achieve real-world practice change for all populations.
In this CMEO Snack, expert faculty will discuss the role of HIV testing in connecting individuals to the care continuum, with a focus on global testing guidelines. Faculty will also explore strategies for increasing HIV testing uptake across the socioeconomic spectrum by reviewing effective communication approaches to address stigma, bias, and access/resource barriers; comparing testing practices and guideline recommendations by region; and outlining rapid-start and same-day ART initiation workflows following diagnosis.
In this CME Outfitters Snack, expert faculty will assist learners to explore the role of FGF21 across metabolic and fibrotic pathways, interpret emerging clinical evidence for FGF21 analogues in clinically significant MASH, and examine the scientific rationale for targeting the FGF21 pathway in patients with compensated cirrhosis due to MASH.
As the fourth and final segment, this conversation brings the series full circle. After framing obesity’s heterogeneity, exploring amylin biology, and considering phenotype-guided care, it turns to the closing question: as these therapies arrive, how do we evaluate them — and whom might they help? A forward-looking, evidence-grounded finish for clinicians preparing for what comes next. All data discussed are investigational and presented as such.
